AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday, seeking to build its pipeline of cell-based cancer treatments.

T-cell therapy company Neogene Therapeutics is being purchased by multinational pharma giant AstraZeneca in a deal potentially worth as much as $320 63.4 F. Los Angeles. Friday, Jun 20, 2025. Log ...

T-cell therapy company Neogene Therapeutics is being purchased by multinational pharma giant AstraZeneca in a deal potentially worth as much as $320 million that could greatly strengthen the ...

Investing.com -- AstraZeneca PLC (LON:AZN) has signed a $320 million cash and debt deal to acquire bio-technology group Neogene Therapeutics, as the U.K. drugmaker looks to expand its cancer ...

AstraZeneca’s deal to acquire Neogene comes as the biotech moves its research into clinical testing with its lead program, NT-125. This cell therapy is designed to carry up to five neoantigen ...

Learn about the time period that took place 23 to 2.6 million years ago. 3 min read From afar, Earth looked much as it does today when the Neogene period began. But looks are deceiving. Mountains ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) said that it agreed to buy all outstanding equity of Neogene Therapeutics for a total consideration of up to $320 million, on a cash and debt free basis.

With the Neogene acquisition and a CAR-T in phase 1 courtesy of a Chinese partnership, AstraZeneca hopes to create a cell therapy “library.” ...

AstraZeneca has agreed to acquire the T-cell receptor (TCR) therapy company Neogene for $200 million on closing and up to $120 million in other payments.

Neogene Therapeutics. BioPharma, Pharma AstraZeneca Puts Up $200M in Solid Bet on Startup’s Take on Cancer Cell Therapy AstraZeneca is jumping into the chase for cell therapies that address ...

AstraZeneca said on Tuesday it would acquire Neogene Therapeutics, a developer of cell-based cancer treatments, for up to $320 million, as the London-listed drugmaker seeks to bolster its oncology ...